Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767241105> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2767241105 endingPage "S2080" @default.
- W2767241105 startingPage "S2080" @default.
- W2767241105 abstract "Bevacizumab has been demonstrated significant survival benefits in addition to chemotherapy in patients with advanced NSCLC from several large scale randomized control trials. We aimed to explore the clinical impact of first-line bevacizumab-contained regimen (B+) versus non-bevacizumab regimen (non-B) for patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC) in the real world setting. From July 2009 to December 2016, patients with advanced NS-NSCLC who received first-line therapy with or without bevacizumab were retrospectively collected from Cancer Hospital Chinese Academy of Medical Sciences. Primary outcome was progression-free survival (PFS), and the secondary objectives were objective response rate (ORR), disease control rate (DCR) and safety. Meanwhile exploratory analysis was conducted in each sub-groups regarding to EGFR and ALK status. 149 patients met selection criteria, 62 in B+ group and 87 in non-B group. Chemotherapy was the based treatment in each group, 57/62 and 71/87 respectively. Median follow-up time was 10.7 months. The baseline characteristics were well balanced. In overall population, median PFS were significantly longer in B+ than in the non-B group: 9.7 vs 7.0 months, HR 0.52, 95% CI 0.30-0.91, P=0.0184. Both ORR and DCR had improved trends in B+ group. In wild type patients, median PFS of B+ group was 11.3 months compared with 5.5 months in the non-B group (HR, 0.43; 95% CI, 0.20-0.91; P=0.0234). In wild-type and unknown population, median PFS was 11.3 months (B+ group) comparing to 6.0 months (non-B group) (HR, 0.53; 95% CI, 0.28-1.02; P=0.0520). The ORR and DCR had consistently similar response in subgroups comparison (Table 1). Safety profile was acceptable in both groups and no new unexpected findings were found. Our real world analysis further confirmed that bevacizumab-contained therapy as first line treatment was indeed superior in clinical benefits than non-bevacizumab regimen in Chinese patients with advanced NS-NSCLC in a real world." @default.
- W2767241105 created "2017-11-17" @default.
- W2767241105 creator A5003026237 @default.
- W2767241105 creator A5012563966 @default.
- W2767241105 creator A5019248649 @default.
- W2767241105 creator A5030376299 @default.
- W2767241105 creator A5032552452 @default.
- W2767241105 creator A5036674932 @default.
- W2767241105 creator A5075039916 @default.
- W2767241105 creator A5079569446 @default.
- W2767241105 creator A5084227396 @default.
- W2767241105 date "2017-11-01" @default.
- W2767241105 modified "2023-10-18" @default.
- W2767241105 title "P2.01-030 Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC" @default.
- W2767241105 doi "https://doi.org/10.1016/j.jtho.2017.09.1132" @default.
- W2767241105 hasPublicationYear "2017" @default.
- W2767241105 type Work @default.
- W2767241105 sameAs 2767241105 @default.
- W2767241105 citedByCount "0" @default.
- W2767241105 crossrefType "journal-article" @default.
- W2767241105 hasAuthorship W2767241105A5003026237 @default.
- W2767241105 hasAuthorship W2767241105A5012563966 @default.
- W2767241105 hasAuthorship W2767241105A5019248649 @default.
- W2767241105 hasAuthorship W2767241105A5030376299 @default.
- W2767241105 hasAuthorship W2767241105A5032552452 @default.
- W2767241105 hasAuthorship W2767241105A5036674932 @default.
- W2767241105 hasAuthorship W2767241105A5075039916 @default.
- W2767241105 hasAuthorship W2767241105A5079569446 @default.
- W2767241105 hasAuthorship W2767241105A5084227396 @default.
- W2767241105 hasBestOaLocation W27672411051 @default.
- W2767241105 hasConcept C126322002 @default.
- W2767241105 hasConcept C143998085 @default.
- W2767241105 hasConcept C168563851 @default.
- W2767241105 hasConcept C2776256026 @default.
- W2767241105 hasConcept C2776694085 @default.
- W2767241105 hasConcept C2777785397 @default.
- W2767241105 hasConcept C2777802072 @default.
- W2767241105 hasConcept C2780739268 @default.
- W2767241105 hasConcept C2781413609 @default.
- W2767241105 hasConcept C2908647359 @default.
- W2767241105 hasConcept C71924100 @default.
- W2767241105 hasConcept C99454951 @default.
- W2767241105 hasConceptScore W2767241105C126322002 @default.
- W2767241105 hasConceptScore W2767241105C143998085 @default.
- W2767241105 hasConceptScore W2767241105C168563851 @default.
- W2767241105 hasConceptScore W2767241105C2776256026 @default.
- W2767241105 hasConceptScore W2767241105C2776694085 @default.
- W2767241105 hasConceptScore W2767241105C2777785397 @default.
- W2767241105 hasConceptScore W2767241105C2777802072 @default.
- W2767241105 hasConceptScore W2767241105C2780739268 @default.
- W2767241105 hasConceptScore W2767241105C2781413609 @default.
- W2767241105 hasConceptScore W2767241105C2908647359 @default.
- W2767241105 hasConceptScore W2767241105C71924100 @default.
- W2767241105 hasConceptScore W2767241105C99454951 @default.
- W2767241105 hasIssue "11" @default.
- W2767241105 hasLocation W27672411051 @default.
- W2767241105 hasOpenAccess W2767241105 @default.
- W2767241105 hasPrimaryLocation W27672411051 @default.
- W2767241105 hasRelatedWork W1989906472 @default.
- W2767241105 hasRelatedWork W2039727128 @default.
- W2767241105 hasRelatedWork W2080607747 @default.
- W2767241105 hasRelatedWork W2101986864 @default.
- W2767241105 hasRelatedWork W2169335753 @default.
- W2767241105 hasRelatedWork W2325657449 @default.
- W2767241105 hasRelatedWork W2387455091 @default.
- W2767241105 hasRelatedWork W2745803145 @default.
- W2767241105 hasRelatedWork W3029430426 @default.
- W2767241105 hasRelatedWork W4317566941 @default.
- W2767241105 hasVolume "12" @default.
- W2767241105 isParatext "false" @default.
- W2767241105 isRetracted "false" @default.
- W2767241105 magId "2767241105" @default.
- W2767241105 workType "article" @default.